Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

doi:10.1200/JCO.23.00943

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2024

Russell Nigel H, Wilhelm-Benartzi Charlotte, Othman Jad, Dillon Richard, Knapper Steven, Batten Leona M, Canham Joanna, Hinson Emily L, Betteridge Sophie, Overgaard Ulrik Malthe, Gilkes Amanda, Potter Nicola, Mehta Priyanka, Kottaridis Panagiotis, Cavenagh Jamie, Hemmaway Claire, Arnold Claire, Freeman Sylvie D, Dennis Mike

Abstract excerpt

PURPOSE: To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. PATIENTS AND METHODS: One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytarabine

Share to fms-Like Tyrosine Kinase 3

Share to Granulocyte Colony-Stimulating Factor

Share to Neoplasm Recurrence, Local

Share to Progression-Free Survival

Share to Recurrence

Share to Vidarabine

Source

Open in PubMed Open full text

Identifiers

PMID: 38215358
DOI: 10.1200/JCO.23.00943
PMCID: PMC11003505

Genes

NPM1
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.PMID 38215358Read ↗

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study.Semantic proximity Read ↗

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.Semantic proximity Read ↗

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.Semantic proximity Read ↗

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialSemantic proximity Read ↗

Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.Semantic proximity Read ↗

KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.Semantic proximity Read ↗

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”Semantic proximity Read ↗

Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.Semantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Semantic proximity Read ↗

Intermediate-risk acute myeloid leukemia therapy: current and future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.